ERBB2 and neoplasm: Beyond HER2 amplification, other molecular targets such as BRAF mutation, RET fusion, NTRK fusion, high tumor mutation burden, or deficient mismatch repair/high microsatellite instability have been identified as biomarkers for various anti-cancer agents [6].